December 19th 2024
Scinai Bioservices Inc. has been established in Delaware as the company's new US-based subsidiary, which will serve biotech companies in early stage drug development.
The evolution of therapeutic modalities drives the adoption of single-use technologies.
Using Receptor Architecture to Improve CAR-T Cell Sensitivity in Oncology (ASGCT 2024)
May 11th 2024Phillip Gregory, PhD, senior vice-president and head of Regeneron Cell Medicines, Regeneron, discussed how engineering receptor architecture can be a tool to improve CAR-T cell sensitivity to tumor antigens.